Global Markets and Technologies for Pandemic Control
The total market for pandemic infectious disease products broken down by disease type was $31.6 billion in 2011 and $35.6 billion in 2012. The market is expected to rise at a CAGR of 9.3% and reach nearly $55.6 billion by 2017.
The report provides:
- An overview of the products in development to treat bacterial diseases, especially those caused by drug-resistant organisms, and HIV/AIDS
- Analyses of market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Clarification of the HIV/AIDS pandemic and ongoing efforts to control it
- Discussion of emerging threats, such as multidrug-resistant tuberculosis, West Nile virus and other serious viral diseases
- Trends based on projected sales through 2017 for new products, including supporting analyses for projections.
- Comprehensive company profiles of major players.
SCOPE OF REPORT
This report provides an in-depth look at the emerging pandemic of antibiotic resistance and the established viral pandemic of HIV/AIDS. It also provides historical, epidemiological and market information on hepatitis B and C, tuberculosis and malaria. This report also investigates bacterial and viral diseases that are emerging as health threats because of inadequate or nonexistent preventive and/or therapeutic products to combat them.
Antibiotic-resistant organisms wreak havoc with international healthcare systems as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE) and Clostridium difficile (C. diffile) become more pervasive. These infections represent future pandemics if no suitable antibiotics are developed to counteract them. At present, each is problematic, but remains at an epidemic level, primarily within healthcare institutions and nursing facilities. Consequently, these infections are covered descriptively within the report, but are not yet classified as pandemics, nor measured quantitatively as part of the overall market for pandemics.
The report outlines the available preventative and diagnostic products used to combat current and future pandemic infections and projects markets for these products. Forecasts are provided for the diagnostic and pharmaceutical markets for products to treat HIV/AIDS, hepatitis B and C, malaria and tuberculosis. Forecasts and trends are gleaned from industry sources as well as from an assessment of emerging products and technologies.
The causes, the extent of impact and strategies to monitor, treat and prevent resistant diseases are assessed. The mechanisms by which drugs function to combat resistant microbes are described. Drugs that show promise of long-term activity (i.e., low likelihood of resistance) and their effects on the market are assessed.
Peggy S. Lehr is the BCC Research analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder, and a MS in Communication from the University of Denver. Ms. Lehr has worked as a researcher, editor and publisher within the publishing industry for both for-profit and not-for-profit organizations.
The market for "new antibiotics" and HIV/AIDS treatments was $6.2 billion in 2003 and is rising at an AAGR (average annual growth rate) of 9.1%. It is expected to reach $10.1 billion in 2008.
New antibiotics (products introduced in 2000 or later) will move from a market share of just under 4% in 2003 to a projected market share of more than 20% in 2008, rising at an AAGR of nearly 34%.
Drugs to treat HIV/AIDS will not see as dramatic an annual growth rate, but will continue to expand at a healthy pace as a result of recently introduced products.
In this category, combination products are taking market share away from single-chemical agents, and this trend will continue throughout the forecast period.